利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.054 秒)

    COMPOUNDS AND METHODS OF TREATING DIABETES
    3.
    发明申请
    COMPOUNDS AND METHODS OF TREATING DIABETES 审中-公开
    化合物和治疗糖尿病的方法

    公开(公告)号：WO2012112962A1

    公开(公告)日：2012-08-23

    申请号：PCT/US2012/025751

    申请日：2012-02-17

    申请人： MEDIVATION TECHNOLOGIES, INC. ,  PROTTER, Andrew, Asher ,  CHAKRAVARTY, Sarvajit

    发明人： PROTTER, Andrew, Asher ,  CHAKRAVARTY, Sarvajit

    IPC分类号： A61K31/55 ,  C07D471/00

    CPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/439 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/519 ,  A61K31/55 ,  A61K45/06 ,  C07D471/08 ,  C07D471/14 ,  C07D471/18 ,  C07D487/04 ,  C07D487/08 ,  C07D487/14 ,  C07D487/18

    摘要： Hydrogenated pyrido[4,3-b]indoles, pyrido [3, 4-b] indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor a 2A . The compounds may also bind to and are an antagonist of the adrenergic receptor α 2B ; or the compounds are not antagonists of the adrenergic receptor α2β and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.

    摘要翻译： 描述了氢化吡啶并[4,3-b]吲哚，吡啶并[3,4-b]吲哚和氮杂环[4,5-b]吲哚。 该化合物可以结合肾上腺素能受体a2A并且是拮抗剂。 该化合物还可以结合并且是肾上腺素受体a2B的拮抗剂; 或者化合物不是肾上腺素能受体α2β的拮抗剂，并且化合物与减少或预期降低个体血压的第二药剂一起施用。 该化合物可用于治疗，例如调节血糖水平，增加胰岛素分泌并治疗对胰岛素产生增加或预期是响应的疾病或病症。 特别描述了化合物治疗2型糖尿病的用途。

    NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B] INDOLES AND METHODS OF USE
    7.
    发明申请
    NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B] INDOLES AND METHODS OF USE 审中-公开
    新的2,3,4,5-四氢-1H-吡咯并[4,3-B]吲哚和使用方法

    公开(公告)号：WO2011014695A1

    公开(公告)日：2011-02-03

    申请号：PCT/US2010/043774

    申请日：2010-07-29

    申请人： MEDIVATION TECHNOLOGIES, INC. ,  JAIN, Rajendra, Parasmal ,  CHAKRAVARTY, Sarvajit

    发明人： JAIN, Rajendra, Parasmal ,  CHAKRAVARTY, Sarvajit

    IPC分类号： A01N43/38 ,  A61K31/405

    CPC分类号： A61K31/405 ,  A61K31/404

    摘要： This disclosure relates to compounds that may be used to modulate a histamine receptor in an individual. Compounds are described, including new 2,3,4,5-tetrahydro-lH-pyrido[4,3-b]indole compounds. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

    摘要翻译： 本公开涉及可用于调节个体中组胺受体的化合物。 描述了化合物，包括新的2,3,4,5-四氢-1H-吡啶并[4,3-b]吲哚化合物。 还提供了包含化合物的药物组合物，以及在各种治疗应用中使用化合物的方法，包括治疗认知障碍，精神病性障碍，神经递质介导的病症和/或神经元病症。

    FUSED CYCLOALKYL-PYRIMIDINE COMPOUNDS AND USES THEREOF
    9.
    发明申请
    FUSED CYCLOALKYL-PYRIMIDINE COMPOUNDS AND USES THEREOF 审中-公开
    稠合的环烷基 - 嘧啶化合物及其用途

    公开(公告)号：WO2016003827A2

    公开(公告)日：2016-01-07

    申请号：PCT/US2015/038140

    申请日：2015-06-26

    申请人： MEDIVATION TECHNOLOGIES, INC.

    发明人： CHAKRAVARTY, Sarvajit ,  RAI, Roopa ,  GREEN, Michael, John ,  ANSARI, Amantullah ,  AGARWAL, Anil, Kumar

    IPC分类号： A61K31/517 ,  C07D401/14

    CPC分类号： C07D403/14 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

    摘要： Fused cycloalkyl-pyrimidine compounds that are kinase inhibitors, such as multi-kinase inhibitors, are provided. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused cycloalkyl-pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused cycloalkyl- pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.

    摘要翻译： 提供了作为激酶抑制剂的稠合环烷基 - 嘧啶化合物，例如多激酶抑制剂。 这些化合物可用于治疗癌症的方法中。 还提供了含有稠合的环烷基 - 嘧啶化合物和药学上可接受的载体的药物组合物，以及包含稠合的环烷基 - 嘧啶化合物或其盐的试剂盒以及例如在治疗癌症的方法中的使用说明。